Literature DB >> 29056230

Correlation between gamma-glutamyl transpeptidase activity and outcomes after Kasai portoenterostomy for biliary atresia.

Kyong Ihn1, In Geol Ho2, Eun Young Chang3, Seok Joo Han4.   

Abstract

BACKGROUND/
PURPOSE: The role of serum gamma-glutamyl transpeptidase (GGT) levels in predicting clinical outcomes after Kasai portoenterostomy (KPE) is unknown. This study analyzed whether postoperative GGT along with the aspartate aminotransferase-to-platelet ratio index (APRi) predicted prognosis of biliary atresia (BA).
METHODS: Data were retrospectively reviewed for 169 BA patients categorized into jaundice-free (JF) (total bilirubin <2.0 mg/dL ≤6 months post-KPE) and persistent jaundice (PJ) groups (total bilirubin ≥2.0 mg/dL ≤6 months post-KPE). Serum biochemical markers, including GGT levels, were measured monthly after KPE, and mean GGT levels and APRi were compared between groups. Factors predicting native liver survival (NLS) were determined using a Cox regression analysis.
RESULTS: GGT concentrations >550 IU/L at month 5 (hazard ratio: 1.74, P < 0.05), an APRi >0.605 at month 4 (hazard ratio: 3.78, P = 0.001), and being jaundice-free at 6 months (hazard ratio: 5.49, P < 0.001) were independent risk factors for decreased NLS.
CONCLUSIONS: Serum GGT concentrations >550 IU/L at month 5 and an APRi >0.605 at month 4 post-KPE were associated with significantly lower NLS rates. Among JF patients, those with GGT concentrations >550 IU/L at month 5 and APRi >0.605 at month 4 showed poorer outcomes. TYPE OF STUDY: Retrospective comparative study LEVEL OF EVIDENCE: Level III.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aspartate aminotransferase-to-platelet ratio index; Biliary atresia; Gamma-glutamyl transpeptidase; Kasai portoenterostomy; Prognosis

Mesh:

Substances:

Year:  2017        PMID: 29056230     DOI: 10.1016/j.jpedsurg.2017.10.001

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  6 in total

1.  Short- and long-term outcomes after Kasai operation for type III biliary atresia: Twenty years of experience in a single tertiary Egyptian center-A retrospective cohort study.

Authors:  Emad Hamdy Gad; Yasmin Kamel; Tahany Abdel-Hameed Salem; Mohammed Abdel-Hafez Ali; Ahmed Nabil Sallam
Journal:  Ann Med Surg (Lond)       Date:  2021-01-23

2.  Modeling Outcomes in Children With Biliary Atresia With Native Liver After 2 Years of Age.

Authors:  Veena Venkat; Vicky L Ng; John C Magee; Wen Ye; Kieran Hawthorne; Sanjiv Harpavat; Jean P Molleston; Karen F Murray; Kasper S Wang; Nisreen Soufi; Lee M Bass; Estella M Alonso; Jorge A Bezerra; M Kyle Jensen; Binita M Kamath; Kathleen M Loomes; Cara L Mack; Philip Rosenthal; Benjamin L Shneider; Robert H Squires; Ronald J Sokol; Saul J Karpen
Journal:  Hepatol Commun       Date:  2020-10-03

3.  Biomarkers for the diagnosis and post-Kasai portoenterostomy prognosis of biliary atresia: a systematic review and meta-analysis.

Authors:  Lin He; Dennis Kai Ming Ip; Greta Tam; Vincent Chi Hang Lui; Paul Kwong Hang Tam; Patrick Ho Yu Chung
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

4.  A Novel Model for Predicting the Clearance of Jaundice in Patients With Biliary Atresia After Kasai Procedure.

Authors:  Yimao Zhang; Qi Wang; Siyu Pu; Junxiang Wang; Bo Xiang; Juxian Liu; Shuguang Jin
Journal:  Front Pediatr       Date:  2022-01-31       Impact factor: 3.418

5.  Low gamma-glutamyl transpeptidase levels at presentation are associated with severity of liver illness and poor outcome in biliary atresia.

Authors:  Song Sun; Shan Zheng; Chun Shen; Rui Dong; Kuiran Dong; Jingying Jiang; Yifan Yang; Gong Chen
Journal:  Front Pediatr       Date:  2022-09-23       Impact factor: 3.569

6.  Long-Term Effects of Kasai Portoenterostomy for Biliary Atresia Treatment in Russia.

Authors:  Anna Degtyareva; Alexander Razumovskiy; Nadezhda Kulikova; Sergey Ratnikov; Elena Filippova; Ekaterina Gordeeva; Marina Albegova; Denis Rebrikov; Anna Puchkova
Journal:  Diagnostics (Basel)       Date:  2020-09-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.